List of Publications

1. Kotzé H.F., Badenhorst P.N., Lamprecht S., Meiring S.M., Van Wyk C, Nuyts K., Stassen J.M., Vermylen J., Deckmyn H. (1995).  Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model.  Thrombosis and Haemostasis 74: 751-757.
2. Meiring S.M., Kotzé H.F., Pretorius G.H.J., Badenhorst P.N. (1995).  ‘n In vitro - vloeikamer as model om die hemostatiese funksie van lewende in situ - endoteelselle te bepaal.  Die Suid-Afrikaanse Tydskrif vir Wetenskap en Tegnologie, 14(4): 102 - 110.
3. Meiring S.M., Lötter M.G., Badenhorst P.N., Bucha E., Nowak G., Kotzé H.F. (1999).  Sites of elimination and pharmacokinetics of recombinant ¹³¹I-lepirudin in baboons.  Journal of Pharmaceutical Sciences , 88(5): 523-529.
4. Meiring SM, Kotzé HF, Pretorius GHJ, Badenhorst PN. (1999).  Die toepassing van peptiedblootlegging op fage in trombose en hemostase (The application of phage display technology in thrombosis and haemostasis). Suid-Afrikaanse Tydskrif vir Natuurwetenskap en Tegnologie (South African Journal of Science and Technology) 18:76-81.
5. Cauwenberghs N, Meiring M, Vautarin S, Van Wyk V, Lamprecht S, Roodt JP, Novak L, Harsfalvi J, Deckmyn H. Kotzé HF. (2000).  Antithrombotic effect of platelet glycoprotein Ib blocking monoclonal antibody Fab fragments in non-human primates.  Arteriosclerosis, Thrombosis and Vascular Biology 20:1347-1353.
6. Viaene A., Crab A., Meiring M., Pritchard D., Deckmyn H. June (2001). Identification of a collagen-binding protein from Necator americanus by using a cDNA-expression phage library.  Journal of Parasitology 87(3): 619-625.
7. 7.S.M. Meiring, J. Harsfalvi, V. van Wyk, P.N. Badenhorst, H.F. Kotzé (2002).  In vitro effect of a novel thrombin inhibition peptide, TIP, selected by phage display technology.  Thrombosis Research 107: 365-371.
8. Wu D, Meiring SM, Kotzé HF, Deckmyn H, Cauwenberghs N (2002).  Inhibition of platelet glycoprotein Ib, Glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons.  Arterioscleorsis Thrombosis and Vascular Biology 22: 323-328.
9. Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring SM, Depraetere H, Kotzé HF, Deckmyn H (2002).  Inhibition of the von Willebrand-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons.  Blood 99:3623-3628.
10. Meiring SM, Badenhorst PN, Kelderman M (2005).The use of an algoritm fot the Laboratory Diagnosis of Von Willebrand Disease.  Medical Technology SA 19: 15-18.
11. Meiring SM, Badenhorst PN, Kelderman M (2005). The use of an algorithm for the laboratory diagnosis of von WIllebrand disease.  Medical Technology SA 19(1): 15-18.
12. Meiring SM, Badenhorst PN, Kelderman M (2005).  A rapid and cost-effective method to visualise von Willebrand Factor multimeres in plasma.  Medical Technology SA 19(2): 15-20.
13. Meiring SM, Roets CE, Badenhorst PN (2006).  Funksionele beskrywing van ’n faktor VIIa-inhiberende peptied, IP-7, geselekteer deur faagblootleggingstegnologie. Die Suid Afrikaanse Tydskrif vir Wetenskap en Tegnologie.  25(4):209-220.
14. Mansvelt E, Jongh G, Wessels G, Fourie E, Meiring SM, Tuddenham E. Haemophilia A in a female patient: 04 PO 67 (2006). Haemophilia. 12 Suppl. 2:10.
15. Meiring SM, Badenhorst PN, Kelderman M (2007). Performance and utility of a cost-effective collagen binding assay for the laboratory diagnosis of Von Willebrand disease.  Clinical Chemistry and Laboratory Medicine.  45(8): 1068-1072.
16. Favaloro EJ, Bonar R, Meiring SM, Street A, Marsden K (2007). 2B or not 2B?  Disparate discrimination of functional VWF discordance using different assay panes or methodologies may lead to success or failure in the early identification of Type 2B VWD.  Thrombosis and Haemostasis 98: 346 – 358.
17. Simon F de Meyer, Stephanie Staelens, Philip N Badenhorst, Henry Pieters, Seb Lamprecht, Jan Roodt, Stefan Janssens, Muriel Meiring, Karen Vanhoorelbeke, André Bruwer, Stephen Brown, Hans Deckmyn. Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor – collagen interaction in baboons.  Thrombosis and Haemostasis 2007; 98: 1343-1349.
18. Coetzee M, Mothabeng S, Meiring M, Nel M, Brussow M (2008).  The prevalence of risk factors for thrombosis in a random sample of haemophilia A patients in Central South Africa 14 .  Haemophilia
19. Meiring SM, Vermeulen J, Badenhorst PN (2009).  Development and Functional Characterisation of an Inhibitory Antibody Fragment to Human Tissue Factor. Drug Development Research 70:199-205.
20. Favaloro EJ, Thom J, Patterson D, Just S, Baccala M, Dixon T, Meiring SM, Koutts J, Rowell J, Baker R (2009).  Potential supplementary utility of combined PFA-100 a functional VWF testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.  Blood Coagulation and Fibrinolysis 20(6): 475-483.
21. Meiring SM, Kelderman M, Badenhorst PN (2009).  Laboratory diagnosis of Von Willebrand Disease. European Haematology 3(1): 33-36.
22. Feys HB, Roodt J, Vandeputte N, Pareyn I, Lamprecht S, Janse Van Rensburg W, Anderson PJ, Budde U, Louw VJ, Meiring M, Deckmyn H, Vanhoorelbeke K (2010).  Thrombotic thrombocytopenic purpura directly inked with ADAMTS13 inhibition in the baboon (Papio ursinus).  Submitted to Blood.
23. Jafta AD, Meiring SM, Conradie C (2010).  Valproic Acid associated platelet dysfunction: Case Report.  African journal of Haematology and Oncology 1(2): 15.
24. Chen W, Leiter A, Dong Y, Meiring M, Louw V, Koeffler P (2010).  Cucurbitan B inhibits growth, arrests the cell cycle and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines.  International Journal of Oncology 37(3): 737-743.
25. Meiring SM, Kelderman M, Coetzee MJ, Badenhorst PN (2011). Laboratory Diagnosis and management of von Willebrand Disease in South Africa.  Seminars in Thrombosis and Haemostasis 37(5): 576.

26. Meiring SM, Webb M, Goedhals D, Louw V (2012).  HIV associated Thrombotic Thrombocytopenic Purpura – What we know so far. European Oncology and Haematology, 8(2):89-91.

27. 
    

    Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk D (2012).  Differential sensitivity of Von Willebrand factor (VWF) “activity” assays to large and small molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. Journal of Thrombosis and Haemostasis 10(6): 1043-1054.

28. Malan N, Von Kanel R, Schutte A, Huisman H. Smith W, Mels C, Kruger K, Meiring M, Van Rooyen J, Malan L (2013).  Testosterone and acute stress are associated with fibrinogen and von Willebrand factor in African men: The SABPA study. International Journal of Cardiology 168 (5): 4638-4642.

29. Von Kanel R, Hamer M, Malan N, Scheepers K, Meiring M, Malan L (2013).  Procoagulant reactivity to laboratory acute mental stress in Africans and Caucasionas and its relation to depressive symptom: The SABPA Study.  Thrombosis and Haemostasis 110(5): 977 -986.
30. Favaloro EJ, Bonar R, Meiring M, Duncan E, Mohammed S, Sioufi J, Marsden K (2014). Evaluating errors in the laboratory identification of von Willebrand disease in the real world Thrombosis Research 134: 393-403.
31. Allie S, Stanley A, Bryer A, Meiring M, Combrinck MI (2015). High levels of von Willebrand factor and low levels of its cleaving protease, ADAMTS13, are associated with stroke in young HIV-infected patients. International Journal of Stroke 10(8):1294-1296.
32. Meiring M, Allers W, Le Roux E (2016).  Tissue Factor: a potent stimulator of Von Willebrand factor synthesis by human umbilical vein endothelial cells. International Journal of Medical Science 13(10): 759-764.
33. Favaloro EJ, Bonar RA, Mohammed S, Arbelaez A, Niemann J, Freney R, Meiring M, Sioufi J, Marsden, K. Type 2M von Willebrand disease – more often misidentified than correctly identified. Haemophilia 2016;22:e145-e55. DOI: 10.1111/hae.12903.
34. Meiring M, Myneni S (2017).  Evaluation of a cost-effective ADAMTS13 antigen assay.  Medical Technology SA 31(1): 1-4.
35. Meiring M, Khemisi M, Laker L, Dohmen PM, Smit FE (2017).  Tissue engineered small vellse conuits – the anti-thrombotic effect of re-endothelialisation of decellularized baboon arteries: a preliminary experimental study.  Medical Science Monitor Basic Research 23: 344-251.

I see myself as the go to person for Von Willebrand disease research and diagnosis in South Africa. I also enjoy international recognition by the Von Willebrand factor multimeric analysis assay that used by the RCPA are used forquality assurance programs. I was also invited to discuss the status of diagnosis of Von Willebrand disease in South Africa.  I published in collaboration with Prof. Emmanuel Favaloro of the RCPA on several issues regarding Von Willebrand disease.  My research on the role of Von Willebrand factor in haemostatic disorders has lead to collaborations with international and national laboratories. We found that Von Willebrand factor plays a major role in the pathogenesis of hypertension and stoke,  

My research laid the foundation for innovative development of diagnostic assays.  I am the inventor of a South African patent and two provisional international applications. I developed cost-effective assays to diagnose thrombotic thrombocytopaenic purpura (TTP), a thrombotic disorder and Von Willebrand disease (VWD), a bleeding disorder. The test measures the levels of ADAMTS-13, a protein that plays a crtical role in for TTP. The VWF-propeptide assay measures the increased clearance of the VWF molecule.  We use it to determine the half-life of VWF in plasma. Patients with increased VWF clearance probably require alternative treatment strategies than those with normal VWF clearance. The current commercially available assays have only been available for the past two years and are still very expensive and the antibodies used in these assays are produced in animals. We produce antibodies using phage display technology. These highly specialized diagnostic assays are now done in South Africa at a fraction of the cost of commercially available assays.

Service delivery:

My Special Haemostasis laboratory is the only one in South Africa that do all the diagnostic tests needed to accurately diagnose VWF, the most common bleeding disorder in South Africa for both the state and private laboratories.  The laboratory is the only reference laboratory for VWD in the country.

More recently, I expanded the VWD reference center to a Special Haemostasis Testing Facility and concluded a service level agreement between the University of the Free State and the National Health Laboratory Service (NHLS) to increase our diagnostic capability.